Understanding B Cell Memory for an HIV Vaccine
Origins and dynamics of HIV gp120 specific B cell memory in HIV negative high-risk individuals
This research looks at how our immune system's memory B cells respond to HIV in people who are at high risk but don't have the virus, hoping to find clues for a better vaccine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11145798 on NIH RePORTER |
What this research studies
Scientists are working to create an effective vaccine against HIV, and understanding how our immune system responds is a key part of this effort. This project focuses on special immune cells called B cells, which remember past infections and help create antibodies. Researchers are particularly interested in how these memory B cells develop in individuals who are at high risk for HIV but have not yet contracted the virus. By studying these cells, we hope to learn more about how the body naturally tries to protect itself and how a future vaccine could best trigger a strong, lasting defense.
Who could benefit from this research
Good fit: This research is relevant to individuals who are HIV-negative but considered at high risk for HIV acquisition, as it studies their immune responses.
Not a fit: Patients already living with HIV or those not at high risk for acquiring HIV may not directly benefit from this specific research focus on pre-infection immunity.
Why it matters
Potential benefit: If successful, this work could provide crucial insights into designing more effective HIV vaccines that teach the immune system to produce strong, protective antibodies.
How similar studies have performed: Previous vaccine efforts like RV144 and HVTN 702 have shown that specific antibody responses are important, but a fully effective preventative vaccine for HIV remains elusive, making this a novel approach to understanding pre-existing immunity.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Kobie, James J — University of Alabama at Birmingham
- Study coordinator: Kobie, James J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.